| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
PLD2 (phospholipase D2).
|
|---|---|
| ln Vitro |
ML298 is a potent and specific inhibitor of phospholipase D2 with an IC50 of 355 nM. It reduces invasive migration of U87-MG glioblastoma cells. The compound is an effective metabolism inhibitor that prevents cell metabolism by inhibiting phospholipases. ML298 is used as a chemical probe to study PLD2 biology and its role in cell signaling, migration, and cancer progression. It is a valuable tool for studying phospholipase-mediated signaling pathways.
|
| ln Vivo |
In vivo efficacy data for ML298 is limited. The compound is primarily used as an in vitro tool for studying PLD2 biology and cell migration. It reduces invasive migration of glioblastoma cells in vitro, suggesting potential applications in cancer research. Further in vivo studies in tumor xenograft models would be needed to assess its therapeutic potential in cancer and other diseases where PLD2 plays a role.
|
| Enzyme Assay |
The in vitro enzyme assay for PLD2 inhibition uses recombinant human PLD2 enzyme and a phospholipid substrate (e.g., phosphatidylcholine). The enzyme is incubated with the substrate and varying concentrations of ML298 (typically 0.1 nM to 100 µM) at 37°C for 30-60 minutes. The product (phosphatidic acid) is quantified by measuring the release of choline using a choline oxidase-coupled assay or by using radiolabeled substrates. The IC50 is calculated from dose-response curves. Selectivity is assessed by profiling against PLD1 and other phospholipases.
|
| Cell Assay |
In vitro cellular assays are performed using U87-MG glioblastoma cells or other cancer cell lines. Cells are treated with ML298 at concentrations ranging from 0.01 to 100 µM for 24-72 hours. Cell migration and invasion are assessed using Transwell or Boyden chamber assays. Cell proliferation is measured using MTT or CellTiter-Glo assays. PLD2 activity in cells is confirmed by measuring phosphatidic acid production or by using fluorescently labeled phospholipid substrates. Apoptosis is assessed by Annexin V/PI staining and flow cytometry.
|
| Animal Protocol |
In vivo animal model data for ML298 is not extensively reported in the literature. As a research tool for studying PLD2 biology in cancer, the compound would typically be evaluated in mouse xenograft models using glioblastoma or other cancer cell lines. Standard efficacy studies would involve tumor growth inhibition and inhibition of metastasis as primary endpoints. Pharmacokinetic studies would assess oral bioavailability, plasma half-life, and tissue distribution. The compound is primarily used as a molecular probe for in vitro studies.
|
| ADME/Pharmacokinetics |
ML298 free base has a molecular weight of 432.44 g/mol and molecular formula C22H23F3N4O2. It is soluble in DMSO and should be stored as a powder at -20°C. Pharmacokinetic parameters such as oral bioavailability, plasma half-life, and tissue distribution are not extensively characterized in publicly available literature. As a research compound, it is typically used in in vitro assays at concentrations ranging from nanomolar to low micromolar.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available for ML298. As a research compound, it is not intended for human use and has not undergone formal toxicological evaluation. Standard preclinical safety assessments for phospholipase inhibitors would typically include selectivity profiling against a panel of related enzymes to assess off-target effects, hERG channel inhibition for cardiac safety, and CYP450 enzyme inhibition for drug-drug interaction potential. The compound is supplied as a solid and should be stored desiccated at -20°C.
|
| References | |
| Additional Infomation |
ML298 is a research-grade PLD2 inhibitor that reduces invasive migration of glioblastoma cells. It is not approved for clinical use. The compound is also known as ML-298. It is a potent and specific PLD2 inhibitor with IC50 of 355 nM. ML298 is used as a chemical tool to study PLD2 biology, cell signaling, and cancer progression. It is supplied as a free base form with high purity and should be stored desiccated at -20°C.
|
| Molecular Formula |
C22H23F3N4O2
|
|---|---|
| Molecular Weight |
432.4472
|
| Exact Mass |
432.177
|
| CAS # |
1426916-02-0
|
| PubChem CID |
53393916
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
650.5±55.0 °C at 760 mmHg
|
| Flash Point |
347.2±31.5 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.620
|
| LogP |
1.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
659
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CN(CCC12C(=O)NCN2C3=CC(=CC=C3)F)CCNC(=O)C4=CC(=C(C=C4)F)F
|
| InChi Key |
XAPVAKKLQGLNOY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H23F3N4O2/c23-16-2-1-3-17(13-16)29-14-27-21(31)22(29)6-9-28(10-7-22)11-8-26-20(30)15-4-5-18(24)19(25)12-15/h1-5,12-13H,6-11,14H2,(H,26,30)(H,27,31)
|
| Chemical Name |
3,4-difluoro-N-[2-[1-(3-fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl]ethyl]benzamide
|
| Synonyms |
ML 298; ML-298; ML298
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~289.06 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3124 mL | 11.5620 mL | 23.1241 mL | |
| 5 mM | 0.4625 mL | 2.3124 mL | 4.6248 mL | |
| 10 mM | 0.2312 mL | 1.1562 mL | 2.3124 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
